HK1201847A1 - Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases il-6 - Google Patents
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases il-6Info
- Publication number
- HK1201847A1 HK1201847A1 HK15102182.7A HK15102182A HK1201847A1 HK 1201847 A1 HK1201847 A1 HK 1201847A1 HK 15102182 A HK15102182 A HK 15102182A HK 1201847 A1 HK1201847 A1 HK 1201847A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- oncology
- antibodies
- extended
- life
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14810609P | 2009-01-29 | 2009-01-29 | |
US18418209P | 2009-06-04 | 2009-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201847A1 true HK1201847A1 (en) | 2015-09-11 |
Family
ID=42396023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102182.7A HK1201847A1 (en) | 2009-01-29 | 2012-09-18 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases il-6 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20120034212A1 (he) |
EP (1) | EP2391384A4 (he) |
JP (3) | JP2012516158A (he) |
KR (1) | KR20110108398A (he) |
CN (2) | CN104119438A (he) |
AU (1) | AU2010208125B2 (he) |
BR (1) | BRPI1007005A2 (he) |
CA (1) | CA2749200A1 (he) |
HK (1) | HK1201847A1 (he) |
MX (1) | MX337590B (he) |
RU (2) | RU2011135422A (he) |
SG (3) | SG172354A1 (he) |
WO (1) | WO2010088444A1 (he) |
ZA (2) | ZA201104796B (he) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
WO2010088444A1 (en) * | 2009-01-29 | 2010-08-05 | Medimmune, Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
EP3438126B1 (en) * | 2009-09-03 | 2020-08-19 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
WO2012083370A1 (en) * | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
WO2012118813A2 (en) | 2011-03-03 | 2012-09-07 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
KR20140076593A (ko) | 2011-09-30 | 2014-06-20 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
CN110680920A (zh) | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | 诱导针对靶抗原的免疫应答的抗原结合分子 |
SG11201405137QA (en) | 2012-02-24 | 2014-12-30 | Chugai Pharmaceutical Co Ltd | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB |
WO2013175276A1 (en) * | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
CN103772503B (zh) * | 2012-10-22 | 2017-05-10 | 泉盛生物科技股份有限公司 | 介白素‑6抗体及其用途 |
EP2911693A4 (en) * | 2012-10-25 | 2016-04-27 | Medimmune Llc | STABLE, LOW-VISIC ANTIBODY FORMULATION |
US10772940B1 (en) * | 2012-12-11 | 2020-09-15 | University Of Kentucky Research Foundation | Cocaine hydrolase-FC fusion proteins for cocaine and methods for utilizing the same |
US20160185847A1 (en) * | 2012-12-17 | 2016-06-30 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Use of monoclonal antibodies for the treatment of inflammation and bacterial infections |
FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
KR102101987B1 (ko) * | 2013-10-31 | 2020-04-20 | 리제너론 파마슈티칼스 인코포레이티드 | 중화 항체를 검출하기 위한 경합 리간드 결합 분석 |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
US11142571B2 (en) | 2014-11-07 | 2021-10-12 | Sesen Bio, Inc. | IL-6 antibodies |
EP3329018B1 (en) * | 2015-07-31 | 2021-03-31 | Medimmune Limited | Il-6 antagonists for use in treating hepcidin-mediated disorders |
CA3012350A1 (en) * | 2016-02-23 | 2017-08-31 | Sesen Bio, Inc. | Il-6 antagonist formulations and uses thereof |
WO2017177032A2 (en) * | 2016-04-07 | 2017-10-12 | Janssen Biotech, Inc. | Treatment of depression using agents that block binding of il-6 to il-6 receptor |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
CA3087699A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
BR112021001214A2 (pt) | 2018-07-24 | 2021-04-27 | Medimmune, Llc | anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus |
AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
US11059884B2 (en) | 2018-10-09 | 2021-07-13 | Medimmune, Llc | Antibodies directed against Staphylococcus aureus leukotoxins |
US20220127338A1 (en) | 2019-03-13 | 2022-04-28 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
JP2022531331A (ja) | 2019-05-01 | 2022-07-06 | ノヴォ ノルディスク アー/エス | 抗il-6抗体製剤 |
CN111057152B (zh) * | 2019-12-11 | 2022-03-11 | 中国人民解放军第四军医大学 | 一种抗人IL-6Ra单克隆抗体及其应用 |
CA3163270A1 (fr) * | 2019-12-31 | 2021-07-08 | Rene Azoulai | Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires |
WO2021186398A1 (en) | 2020-03-19 | 2021-09-23 | Medimmune Limited | Anti-klebsiella pneumoniae antibodies and uses thereof |
PE20231376A1 (es) | 2020-05-17 | 2023-09-07 | Astrazeneca Uk Ltd | Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos |
AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
JP2023537078A (ja) | 2020-08-10 | 2023-08-30 | アストラゼネカ・ユーケイ・リミテッド | COVID-19を治療及び防止するためのSARS-CoV-2抗体 |
TW202342095A (zh) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | 用於治療和預防covid—19之組成物 |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2024073718A1 (en) * | 2022-09-30 | 2024-04-04 | Sonnet BioTherapeutics, Inc. | Low dose il-6 formulations and methods of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL201461B1 (pl) * | 1998-03-17 | 2009-04-30 | Chugai Pharmaceutical Co Ltd | Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny |
EP1355919B1 (en) * | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
KR20100120246A (ko) * | 2001-11-14 | 2010-11-12 | 센토코 오르토 바이오테크 인코포레이티드 | 항 il-6 항체, 조성물, 방법 및 용도 |
EP1517921B1 (en) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
LT2335725T (lt) * | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
CA2585891A1 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
PE20061324A1 (es) * | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
EP1899477A4 (en) * | 2005-07-01 | 2010-01-20 | Medimmune Inc | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS |
EP1988922A4 (en) * | 2006-02-03 | 2010-06-02 | Medimmune Llc | PROTEIN FORMULATIONS |
WO2007104529A2 (en) * | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
CN101600457B (zh) * | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
WO2008137915A2 (en) * | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
WO2008144763A2 (en) * | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
WO2009003019A1 (en) * | 2007-06-26 | 2008-12-31 | Medimmune, Llc | Methods of treating rsv infections and related conditions |
WO2010088444A1 (en) * | 2009-01-29 | 2010-08-05 | Medimmune, Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
-
2010
- 2010-01-29 WO PCT/US2010/022478 patent/WO2010088444A1/en active Application Filing
- 2010-01-29 SG SG2011046265A patent/SG172354A1/en unknown
- 2010-01-29 BR BRPI1007005A patent/BRPI1007005A2/pt not_active Application Discontinuation
- 2010-01-29 CN CN201410349897.9A patent/CN104119438A/zh active Pending
- 2010-01-29 RU RU2011135422/10A patent/RU2011135422A/ru not_active Application Discontinuation
- 2010-01-29 US US13/146,278 patent/US20120034212A1/en not_active Abandoned
- 2010-01-29 JP JP2011548315A patent/JP2012516158A/ja active Pending
- 2010-01-29 RU RU2015150249A patent/RU2650594C1/ru active
- 2010-01-29 AU AU2010208125A patent/AU2010208125B2/en active Active
- 2010-01-29 EP EP10736433A patent/EP2391384A4/en not_active Ceased
- 2010-01-29 MX MX2011007832A patent/MX337590B/es active IP Right Grant
- 2010-01-29 CN CN2010800103915A patent/CN102387814A/zh active Pending
- 2010-01-29 CA CA2749200A patent/CA2749200A1/en not_active Abandoned
- 2010-01-29 SG SG10201704214VA patent/SG10201704214VA/en unknown
- 2010-01-29 SG SG2014007637A patent/SG2014007637A/en unknown
- 2010-01-29 KR KR1020117019221A patent/KR20110108398A/ko not_active Application Discontinuation
-
2011
- 2011-06-28 ZA ZA2011/04796A patent/ZA201104796B/en unknown
-
2012
- 2012-09-18 HK HK15102182.7A patent/HK1201847A1/xx unknown
- 2012-09-27 ZA ZA2012/07249A patent/ZA201207249B/en unknown
-
2014
- 2014-04-15 US US14/253,161 patent/US20140302058A1/en not_active Abandoned
-
2015
- 2015-06-19 JP JP2015123389A patent/JP2016019517A/ja active Pending
-
2016
- 2016-12-02 US US15/368,499 patent/US20170101468A1/en not_active Abandoned
-
2017
- 2017-06-07 JP JP2017112163A patent/JP2017206519A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2010208125B2 (en) | 2015-02-12 |
CN104119438A (zh) | 2014-10-29 |
SG2014007637A (en) | 2014-03-28 |
KR20110108398A (ko) | 2011-10-05 |
MX2011007832A (es) | 2011-10-06 |
SG172354A1 (en) | 2011-07-28 |
EP2391384A1 (en) | 2011-12-07 |
AU2010208125A1 (en) | 2011-07-21 |
ZA201207249B (en) | 2013-08-28 |
JP2017206519A (ja) | 2017-11-24 |
ZA201104796B (en) | 2018-11-28 |
RU2650594C1 (ru) | 2018-04-17 |
RU2011135422A (ru) | 2013-03-10 |
CN102387814A (zh) | 2012-03-21 |
US20170101468A1 (en) | 2017-04-13 |
US20120034212A1 (en) | 2012-02-09 |
CA2749200A1 (en) | 2010-08-05 |
BRPI1007005A2 (pt) | 2016-03-22 |
WO2010088444A1 (en) | 2010-08-05 |
US20140302058A1 (en) | 2014-10-09 |
MX337590B (es) | 2016-03-11 |
JP2016019517A (ja) | 2016-02-04 |
EP2391384A4 (en) | 2012-12-26 |
SG10201704214VA (en) | 2017-06-29 |
JP2012516158A (ja) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1201847A1 (en) | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases il-6 | |
IL200572A0 (en) | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
IL254664B (he) | נוגדן המזהה גורם מעכב לוקמיה באדם (lif) ושימוש בנוגדנים אנטי– lif בטיפול במחלות הקשורות בשגשוג תאי בלתי רצוי | |
ZA201100974B (en) | Treatment of autoimmune and inflammatory disease | |
ZA201109384B (en) | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases | |
EP2297202A4 (en) | ANTI-IL-6 / IL-6R ANTIBODIES AND METHODS OF USE | |
EP2023955A4 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
SI2254870T1 (sl) | 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 | |
PL2683826T3 (pl) | Zastosowanie aptamerów w terapii i/lub diagnostyce chorób autoimmunologicznych | |
HK1208168A1 (en) | Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease | |
HK1243436A1 (zh) | 特異性配體在msrv相關疾病中的治療用途 | |
HK1148271A1 (zh) | -苄基- -羥基甲基吲唑衍生物及其在治療基於 表達的疾病中的用途 | |
EP2475389A4 (en) | USE OF AN ANTIBODY AGAINST IL6 FOR HEPCIDINE DEDUCTION IN CANCER PATIENTS | |
IL217209A0 (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
SI2066349T1 (sl) | Humanizirana anti-cd19 protitelesa in njihova uporaba v zdravljenju tumorjev, transplantacijah in avtoimunih boleznih | |
EP2420515A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY | |
GB0905970D0 (en) | Depsipeptides and their therapeutic use | |
HU0900195D0 (en) | Diagnosis and treatment of gluten-induced autoimmune diseases | |
PL2265279T3 (pl) | Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych |